

Impact report 2025

EU SFDR
Article 9

KIEGER
dare to care

Kieger UCITS Fund - Kieger Impact Healthcare Fund

Solutions for global health challenges

Dear readers,

We strive to contribute to sustainable positive change, improving access to healthcare, increasing prevention and fostering innovation to help address pressing global health challenges. Through our investments in innovative healthcare companies, we are committed to making a positive difference to patients and the well-being of our society.

In 2017, a WHO study estimated an annual investment gap of USD 400 billion for comprehensive health service delivery in 67 low- and low-to-middle-income countries. This USD 400 billion gap is expected to increase even more following recent changes in US health funding and policies. The US has historically been the largest single provider of global health aid, accounting for about 42% of official development assistance for health in 2023. Recent reductions in funding have led to the closure of hospitals and critical health programs in many low- and middle-income countries, disrupting efforts to combat HIV, tuberculosis, malaria, and other major health challenges. A recent Lancet study estimates that these cuts could result in more than 14 million avoidable deaths by 2030, including over 4.5 million children under five.

These funding decreases have highlighted the vulnerability of health systems in aid-dependent countries and increased the risk of infectious disease spread worldwide. Within the US, shifts in funding priorities have affected public health infrastructure by reducing support to key agencies such as the CDC and NIH, as well as programs supporting Medicaid, mental health, substance abuse, and disease prevention. Changes to federal health agencies have also created uncertainty and care gaps, particularly impacting vulnerable populations.

Therefore, more than ever, we need to channel more funds into healthcare companies that strive to make a positive impact, especially on underserved populations.

Sincerely,

Kieger Healthcare Investment Team

Access & Affordability

512 million

patients reached in relevant markets¹

145 million

patients reached through specific access & affordability programmes²

2,837

generics and biosimilars in drug portfolio

30 million

people insured in relevant markets¹

210

Products on the WHO Essential Medicines List

17 million

virtual visits

Source: Kieger AG, portfolio data as of December 2024, KPIs attributable to portfolio companies

¹ i.e. with high-impact indications and/or in an underserved area

² e.g. voluntary licensing agreements

Source: Kieger AG, portfolio data as of December 2024, KPIs attributable to portfolio companies

Defined as indications set out as an area of focus in the UN SDG 3 targets

7 product therapies

in high-impact indications on the market¹

Innovation

95 pipeline projects

for high-impact indications in clinical development

Source: Kieger AG, portfolio data as of December¹2024, KPIs attributable to portfolio companies

¹ Defined as indications set out as an area of focus in the UN SDG 3 targets

2024

impact highlights

2 million

devices / instruments out in the market helping to prevent cross contamination

18 vaccines

for high-impact indications on the market

177 million

patients reached through early detection and prevention strategies of which:

↳ 164 million

patients benefited from screening and diagnostic tests

↳ 10 million

patients empowered to better manage diabetes

Prevention



Connect with us

Email
info@kieger.com

LinkedIn
Kieger AG

Call us
+41 44 444 18 44

This document has been issued through Kieger AG and is for distribution only under such circumstances as may be permitted by applicable law. This document is for information purposes only and does not constitute an offer. Past performance is not a reliable indicator of future results. The details and opinions contained in this document are provided by Kieger without any guarantee or warranty and are for the recipient's personal use only. All information and opinions contained in this document are subject to change without notice. This document may contain statements that constitute "forward looking statements". A number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. Data source: Statestreet / Factset

Important legal information

This is a marketing communication. The information contained therein is intended only for information purposes and does not represent an offer to purchase or sell financial instruments. The source of the information is considered reliable; however, the accuracy or completeness of such information is not guaranteed. The information is subject to change from time to time without notice. This information neither represents any investment / legal / tax advice, or any recommendation. The Agent (as defined below) points out that every investment decision should be made after consulting an advisor.

Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Please refer to and read carefully the Prospectus of Kieger UCITS Fund (the "Fund") and the Key Investor Information Document ("KIID") of the Kieger UCITS Fund - Kieger Sustainable Healthcare Fund and the Kieger UCITS Fund - Kieger Impact Healthcare Fund in their latest versions before making any final investment decisions. These documents can be obtained in English from the website <https://kieger.com/ucits> or any agents as further described below.

A decision to invest in the sub-fund should take into account all the characteristics or objectives of the sub-fund as disclosed in the Prospectus. A summary of the investor rights is available in English at <https://kieger.com/regulatory-disclosures>. Further information about the sustainability-related aspects of the Fund is available at <https://kieger.com/regulatory-disclosures>. The fund is marketing in multiple member states of European Union and Switzerland. The management company reserves the right to terminate the arrangements made for the marketing of the Fund in accordance with Article 93a of the Directive 2009/65/EC.

Information for Swiss Investors:

This is an advertising document. The state of the origin of the fund is Luxembourg. In Switzerland, the representative is Acolin Fund Services AG, Maintower, Thurgauerstrasse 36/38, CH-8050 Zurich, Switzerland, whilst the paying agent is Banque Cantonale de Genève, 17, Quai de l'Île, CH-1204 Geneva. The prospectus, the key information documents or the key investor information documents, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative.

Information for German Investors:

The Fund's Facilities agent in Germany is Acolin Europe AG, with the registered office at Line-Eid-Straße 6, 78467 Konstanz. The Prospectus (in English) and the KIID (in German), may be obtained free of charge at the registered office of the Facilities agent, or electronically by Email facilityagent@acolin.com, or by using the contact form at <https://acolin.com/services/facilities-agency-services>.

Information for Austrian Investors:

The Facility agent according to EU Directive 2019/1160 Article 92, as well as tax representative in Austria, is Erste bank der oesterreichischen Sparkassen AG, with the registered office at Am Belvedere 1, A-1100 Vienna. The Prospectus (in English) and the KIIDs (in German) may be obtained free of charge at the registered office of the Facility agent, or electronically by Email foreignfunds0540@erstebank.at.

Marketing in the European Union:

The issuer of this marketing communication in Europe (excluding Switzerland) is Kieger Capital Partners S.à.r.l. Kieger Capital Partners S.à.r.l. ("Tied Agent") is a tied agent within the meaning of Article 29 (3) of Directive 2014/65/EU ("MiFID II" as implemented in the respective national legislation) of Acolin Europe AG, which is authorised and regulated by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). The Tied Agent is entered in the public register of tied agents held by CSSF in his homecountry Luxembourg. Within the scope of providing financial services ("investment brokerage" within the meaning of Annex I A (1) MiFID II as implemented in the respective national legislation by promotion of the potential investor's willingness to enter into a transaction but excluding the reception and transmission of orders in relation to one or more financial instruments), the Tied Agent acts exclusively on behalf and for the account of Acolin Europe AG and undertakes to exclusively distribute the Kieger UCITS funds.

The information provided by the Tied Agent is intended for informational purposes only and does not represent an offer to purchase or sell financial instruments. All information is provided without any guarantee. This information neither represents any investment / legal / tax advice, nor any recommendation. The Agent points out that every investment decision should be made after consulting an advisor. The information is intended exclusively for professional clients within the meaning of Annex II MiFID II.

The information provided may not be copied or further distributed to third parties without the prior consent of Acolin Europe AG. The information may not be given to persons or companies that do not have their ordinary residence or domicile in the countries in which Acolin Europe AG is authorized to provide financial services. In particular, the information may not be made available to US citizens or persons residing in the USA. This document may not be